Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the second tranche of its non-brokered private placement, raising $405,500 with significant participation from two German family offices. The company issued 20,275,000 units at $0.02 per unit.
Each unit comprises one common share and one purchase warrant, allowing holders to acquire an additional common share at $0.05 within 24 months. The company maintains the right to accelerate the warrant expiry if the stock's volume-weighted average trading price exceeds $0.10 for ten consecutive trading days on the CSE.
The securities issued are subject to a four-month and one-day statutory hold period, with a third and final tranche expected to close shortly.
Predictmedix AI (OTC: PMEDF) has announced the launch of enhanced Smart Health AI Stations across the United States, partnering with Manchester Marketing Group Inc. The initiative targets the rapidly growing population health management market, currently valued at USD 32.94 billion with projected growth to USD 126.16 billion by 2032.
The Smart Health AI Stations provide non-contact health screenings using AI technology for real-time vitals monitoring and substance-induced impairment detection. Ten units are being considered for demonstration to corporate and government entities across the USA. The technology will be showcased through partnerships extending to Pakistan, Dubai, and Sub-Saharan Africa.
The stations offer applications in workplace wellness, healthcare screening, public safety, education, and government sectors, providing real-time health assessments and data-driven wellness insights.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has successfully closed the first tranche of its non-brokered private placement, raising $320,000 through the issuance of 16,000,000 units at $0.02 per unit. Each unit comprises one common share and one purchase warrant, exercisable at $0.05 per share for 24 months.
The warrant expiry date may be accelerated if the company's shares trade at $0.10 or higher for ten consecutive trading days on the CSE, with a minimum 30-day notice to holders. The proceeds will be used to expand U.S. market opportunities for Predictmedix's AI-driven health management solutions in enterprise and government sectors.
Additionally, the company granted 2,000,000 stock options to a consultant, exercisable at $0.05 per share with a one-year term. All securities issued are subject to a four-month and one-day statutory hold period.
Predictmedix AI (PMEDF) announced a strategic repositioning, shifting its focus from traditional healthcare to AI-powered health management technologies. The company is developing solutions for workplace safety, workforce readiness, and public sector health screening.
The company's AI-driven solutions aim to help businesses assess workforce readiness through detection of fatigue, vital signs monitoring, and substance impairment screening. These technologies are designed to integrate with HR, compliance, and safety protocols in industries such as manufacturing, logistics, energy, construction, and defense.
Additionally, Predictmedix AI is exploring opportunities in defense, public safety, and education sectors, focusing on workplace health monitoring applications and AI-driven assessments for law enforcement and military personnel.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has announced a non-brokered private placement offering of up to 50,000,000 units at C$0.02 per unit, aiming to raise up to C$1,000,000. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of one common share at C$0.05 within 24 months of closing.
The company has begun receiving commitments for the placement, according to COO Dr. Rahul Kushwah. The proceeds will be allocated to general working capital and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors. All securities issued will have a four-month and one-day statutory hold period.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.